Beyond the H. pylori headlines, mastic gum has real human trial data for cholesterol, inflammation, Crohn's disease markers, and oral health. Here's the full evidence picture, mechanism by mechanism.
Mastic gum's reputation rests almost entirely on its association with *H. pylori* and stomach ulcers, but that's actually the most contested part of its evidence base (see our companion deep-dive on the H. pylori research). Less discussed — and better supported by clean, published human trials — are mastic gum's effects on cholesterol, systemic inflammation, and oral health. Here's the full picture.
Mastic gum is the hardened, aromatic resin harvested from *Pistacia lentiscus var. Chia*, a tree that grows almost exclusively in the southern part of the Greek island of Chios — a geographic quirk protected by a European Union Protected Designation of Origin (PDO) status, similar to Champagne. The resin has been chewed, burned as incense, and used medicinally since antiquity; Hippocrates and Dioscorides both referenced it. Modern supplementation typically comes as capsules containing the ground resin or a standardized extract.
A human trial by Triantafyllou and colleagues (*Journal of Ethnopharmacology*, 2011) followed healthy adults with mildly elevated cholesterol taking Chios mastic gum daily and found statistically significant reductions in total cholesterol, LDL cholesterol, and fasting glucose after several weeks, compared to baseline. The proposed mechanism involves mastic gum's triterpenoid compounds (masticadienonic and isomasticadienonic acid), which appear to modulate hepatic lipid metabolism in animal models. This is one of the more surprising and reproducible findings in the mastic gum literature, and it positions mastic gum alongside other plant-derived compounds like berberine and bergamot as a mild, adjunctive metabolic-health supplement — not a replacement for statins in anyone with clinically significant dyslipidemia, but a reasonable addition to a broader protocol.
One of the more clinically interesting mastic gum trials comes from Kaliora and colleagues, who studied Chios mastic gum in patients with mildly-to-moderately active Crohn's disease (*World Journal of Gastroenterology*, 2007). Patients taking mastic gum showed reductions in disease activity index scores and inflammatory markers, including interleukin-6 (IL-6), compared to baseline — a meaningful finding given IL-6's central role in chronic inflammatory disease and its links to broader aging-related inflammation ("inflammaging"). This doesn't make mastic gum a replacement for standard Crohn's therapy, but it's one of the few natural compounds with a published human RCT showing measurable anti-inflammatory activity in an actual inflammatory bowel disease population, rather than just healthy volunteers.
Long before capsules existed, mastic was chewed as a breath freshener and dental aid across the Mediterranean — and modern research backs up at least part of that tradition. Studies on mastic chewing gum have found it reduces salivary counts of *Streptococcus mutans*, the primary bacterium responsible for dental plaque and cavities, and several small trials report measurable reductions in plaque index scores with regular mastic gum chewing. The mechanism appears to combine mild antibacterial activity with the simple mechanical action of chewing, which increases saliva flow (saliva itself has protective, buffering, and antibacterial properties).